Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Photocure ASA ( (PHCUF) ).
Photocure ASA is set to announce its financial results for the fourth quarter and the preliminary full year of 2024 on February 19, 2025. The report and a live investor presentation, hosted by CEO Dan Schneider and CFO Erik Dahl, will be publicly available on the company’s website. This announcement is crucial for stakeholders as it provides insights into the company’s financial health and strategic direction.
More about Photocure ASA
Photocure ASA, known as The Bladder Cancer Company, is a Norwegian firm that provides innovative solutions to enhance the treatment of bladder cancer patients. Their proprietary technology highlights cancer cells by making them glow bright pink, contributing significantly to improved health outcomes globally. Photocure is headquartered in Oslo and is listed on the Oslo Stock Exchange under the ticker PHO.
YTD Price Performance: -4.89%
Average Trading Volume: 1,008
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $138.7M
See more data about PHCUF stock on TipRanks’ Stock Analysis page.
